Search the Newsreel

Myriad Genetics Faces Multiple Investor Investigations

Myriad Genetics (NASDAQ: MYGN) is facing multiple investor investigations from several law firms after reporting weaker-than-expected second-quarter results and sharply reducing its 2026 revenue outlook. The company's stock lost nearly half its value following the announcement, prompting inquiries into whether Myriad Genetics or its …

Dimensional Fund Advisors LP Reduces Stake in Myriad Genetics, Inc. $MYGN

Dimensional Fund Advisors LP significantly reduced its stake in Myriad Genetics, Inc. by 42.6% in the first quarter, selling over half a million shares. This move comes as institutional investors hold a substantial portion of the company, and analysts have become more bearish, issuing …

Assenagon Asset Management S.A. Reduces Holdings in Myriad Genetics, Inc. $MYGN

Assenagon Asset Management S.A. significantly reduced its stake in Myriad Genetics, Inc. by 28.7% in the second quarter, selling over 415,000 shares. This divestment follows Myriad Genetics reporting disappointing quarterly results, missing analyst expectations for both earnings and revenue, and experiencing a year-over-year revenue …

Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (NASDAQ: MYGN) securities. This investigation follows Myriad's Q2 2026 revenue report, which showed an 11% year-over-year decrease and fell short of Wall Street estimates, leading the company …

Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky

Levi & Korsinsky is investigating Myriad Genetics (MYGN) for potential securities law violations after the company reported lower-than-expected Q2 2026 revenue, cut its full-year revenue guidance, and suspended adjusted EBITDA guidance. The investigation focuses on whether Myriad Genetics made materially false or misleading statements …

Myriad Genetics And 2 Other Promising Penny Stocks For Your Watchlist

This article identifies three promising penny stocks—Myriad Genetics (MYGN), Claros Mortgage Trust (CMTG), and Nextdoor Holdings (NXDR)—that exhibit strong financial health despite current challenges. Myriad Genetics is expanding its market reach through strategic partnerships, Claros Mortgage Trust has a solid cash runway despite unprofitability, …

MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS) has initiated an investigation into Myriad Genetics, Inc. (NASDAQ: MYGN) for potential securities law violations. This investigation follows Myriad's Q2 2026 financial results, which showed an 11% year-over-year revenue drop, reduced full-year guidance, and suspended EBITDA guidance, causing …

Myriad Genetics (NASDAQ:MYGN) Lowered to "Sell" Rating by Wall Street Zen

Wall Street Zen has downgraded Myriad Genetics (NASDAQ:MYGN) to a "Sell" rating from "Hold," citing the company's recent earnings miss and declining revenue. The stock opened significantly below its moving averages, and the analyst consensus for Myriad Genetics is now "Reduce" with an average …

MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Myriad (MYGN) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Myriad and would like to discuss your legal rights, contact Bragar Eagel …

Myriad Genetics Inc (MYD.HA) stock price, news, quote and history

State Street Corporation (NYSE: STT) discloses 5.3% holding in Myriad Genetics

State Street Corporation has disclosed a 5.3% beneficial ownership in Myriad Genetics, Inc. (MYGN), amounting to 4,985,060 shares. This ownership is managed through various asset management subsidiaries, with shared voting and dispositive power over the shares. The filing, a SCHEDULE 13G, indicates a passive …

Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating Myriad Genetics, Inc. (MYGN) after the company reported Q2 2026 revenues below Wall Street expectations and significantly cut its full-year 2026 revenue guidance. The firm encourages stockholders to contact them to learn more about the investigation into …

Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential securities claims against Myriad Genetics, Inc. (MYGN) after the company reported significantly lower-than-expected Q2 2026 revenue and drastically cut its full-year 2026 guidance. This announcement followed Myriad Genetics reiterating stronger guidance just three months prior, leading …

MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP

Kirby McInerney LLP has announced an investigation into Myriad Genetics, Inc. (NASDAQ: MYGN) for potential securities fraud. This follows Myriad Genetics' report of an 11% year-over-year revenue decline in Q2 2026, reduced full-year guidance, and a significant stock price drop after the announcement. The …

Myriad Genetics, Inc. (MYGN) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel

Johnson Fistel, PLLP is investigating Myriad Genetics, Inc. (MYGN) for potential federal securities law violations after the company reported an 11% year-over-year revenue decline and reduced its annual guidance. This decline was attributed to issues like lower reimbursement and unfavorable estimate changes, leading to …

Myriad Genetics, Inc. Stock 12‑Month Price Target Cut to $5.34, Implies 87% Upside

Myriad Genetics, Inc.'s average 12-month price target has been lowered by analysts from $5.44 to $5.34, with forecasts ranging from $3 to $10. This updated target suggests an approximate 87% potential upside based on the July 31 closing price. Despite the target cut, the …

Myriad Genetics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Myriad Genetics (MYGN)

Levi & Korsinsky, LLP has announced an investigation into Myriad Genetics (NASDAQ: MYGN) after the company significantly cut its full-year 2026 revenue guidance and suspended adjusted EBITDA guidance. This comes just three months after reaffirming higher revenue projections, leading to investor losses. The firm …

Why Myriad Genetics (MYGN) Is Down 49.0% After Cutting 2026 Revenue Outlook On Prenatal Weakness

Myriad Genetics (MYGN) shares dropped 49% after the company cut its 2026 revenue outlook to US$770-790 million, down from US$190.7 million, primarily due to weaker Prenatal Health test volumes. Despite a narrowed net loss, the reduced forecast highlights ongoing pressure on test volumes and …

Myriad Genetics (MYGN) Missed Q2 And Cut Guidance, Is It Still 54% Below Fair Value?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Myriad Genetics (MYGN) is back in focus after its second quarter 2026 earnings missed expectations and the company cut its full year revenue guidance, …

MYGN Slides As Myriad Genetics Slashes 2026 Revenue Outlook

Myriad Genetics Inc. (MYGN) stock slid by 45.72% after the company slashed its 2026 revenue outlook to $770M-$790M from a prior $860M-$880M, falling short of Street expectations. This reduction was attributed to competitive genetic testing advancements, weaker Q2 performance, and increased payer friction, leading …

Myriad Genetics (MYGN) Stock Sinks As Revenue Reset Deepens Loss Fears

Myriad Genetics (MYGN) stock sharply declined by nearly 47% after reporting a Q2 revenue reset and cutting full-year sales guidance, deepening fears of prolonged losses. Despite some clinical advancements in its oncology portfolio, the company experienced weakened average revenue per test and reduced gross …

Myriad Genetics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:MYGN) 2026-08-01

Myriad Genetics, Inc. (MYGN) released its Q2 2026 earnings call presentation, detailing financial results. The company reported an EPS of -$0.25, missing estimates by $0.19, and revenue of $190.70M, which was down 10.51% year-over-year and missed estimates by $15.33M. This article provides access to …

Myriad Genetics Is Maintained at Hold by TD Cowen

TD Cowen has reiterated its "Hold" rating for Myriad Genetics. The investment bank has also maintained its price target for the company.

[10-Q] MYRIAD GENETICS INC Quarterly Earnings Report

Myriad Genetics Inc. (MYGN) has filed its quarterly earnings report (Form 10-Q) for the period ended June 30, 2026. The company reported a net loss of $43.2 million for Q2 2026 and $77.3 million for the six months ended June 30, 2026. Revenue experienced …

Myriad Genetics (NASDAQ:MYGN) Posts Earnings Results, Misses Estimates By $0.22 EPS

Why Myriad Genetics (MYGN) Shares Are Falling Today

Why Myriad Genetics (MYGN) Shares Are Falling Today What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 46.1% in the afternoon session after the company reported disappointing second-quarter 2026 results that missed Wall Street's expectations and included a reduced full-year forecast. Revenue …

Myriad Genetics Stock Drops Sharply After Hours: What Investors Need to Know

Myriad Genetics Inc. (NASDAQ: MYGN) shares dropped significantly by 37.80% in after-hours trading after the company reported disappointing second-quarter 2026 financial results, including lower revenue, an operating loss, and reduced full-year revenue guidance. The company also suspended its adjusted EBITDA outlook. Despite the overall …

Myriad outlines $770M-$790M 2026 revenue and 66%-67% gross margin ranges while suspending adjusted EBITDA guidance

Earnings Call Insights: Myriad Genetics (MYGN) Q2 2026 MANAGEMENT VIEW * "Second quarter total revenue of $190.7 million was down 11% year-over-year, as volume decreased 1% and revenue per test decreased 9%." (President, CEO & Director Samraat Raha) "Demand for our Cancer Care Continuum …

Myriad Genetics Inc (MYGN) (Q2 2026) Earnings Call Highlights: Revenue Declines 11% Amid Payer ...

This article first appeared on GuruFocus. Total Revenue: $190.7 million, down 11% year over year. Test Volume: Decreased 1% year over year. Average Revenue per Test: Decreased 9% year over year, including an $11 million headwind from lower prior period collections. Cancer Care Continuum …

Myriad Genetics Lowers FY26 Rev Outlook

Myriad Genetics announced a reduction in its revenue outlook for fiscal year 2026. The company did not provide specific reasons for the revised forecast in the provided content.

Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability

Myriad Genetics announced its second quarter 2026 financial results, with revenue of $190.7 million, an 11% decrease year-over-year. The company is implementing new initiatives, including "Ascend," to improve efficiency, productivity, and scalability, and revised its full-year 2026 financial guidance. Despite challenges in Prenatal Health …

Myriad Genetics Q2 Results: Revenue falls 11% YoY

Myriad Genetics Inc. experienced an 11% year-over-year revenue decline to $190.7 million in Q2 2026, leading to a significant 37.8% drop in stock price. The company reported a $38.9 million operating loss and suspended its full-year adjusted EBITDA guidance due to payer friction and …

Myriad Genetics (NASDAQ: MYGN) posts Q2 loss, lowers 2026 revenue view

Myriad Genetics (NASDAQ: MYGN) reported a Q2 2026 net loss of $43.2 million on revenues of $190.7 million, marking an 11% year-over-year decline. The company also lowered its full-year 2026 revenue guidance to $770–$790 million and suspended its Adjusted EBITDA outlook, citing challenges in …